Ten Years of Experience with Drug Therapy of Familial Hypercholesterolemia in Children and Adolescents
; V. Martiníková
; V. Maťoška
; J. Dvořáková
; H. Přindišová
; J. Dudková
; L. Dubská
; M. Loučka
; H. Jenčová
; M. Vodičková
Oddělení klinické biochemie, hematologie a imunologie, Nemocnice Na Homolce, Praha
primář MUDr. M. Průcha, PhD.
; Radiodiagnostické oddělení, Nemocnice Na Homolce, Praha
primářka MUDr. J. Janoušková, CSc.
; Oddělení nukleární medicíny, Nemocnice Na Homolce, Praha
přednosta doc. MUDr. O. Bělohlávek, CSc.
; Institut matematiky a statistiky VŠCHT, Praha
přednosta doc. Ing. M. Loučka, CSc.
Čes-slov Pediat 2006; 61 (7-8): 404-412.
The therapeutic effect of administration of simvastatin on the decrease of total cholesterol in plasma was evaluated in 33 children suffering from heterozygous form of hypercholesterolemia at the age of 10–18 years and living in the Prague agglomeration. The somatic and sexual development was observed, side effects were evaluated clinically and by laboratory methods. Simvastatin proved to be well tolerated in all children (in contrast to low-cholesterol diet or ion-exchange resin therapy applied before). The therapeutic effect of simvastatin was compared with the effects of low-cholesterol diet and the ion-exchange resin therapy in a control group of children and adolescents of the same age. The therapy started with the therapeutic dose of 2.5–5 mg/d in the youngest children, in the older children and adolescents the authors used 10–20 mg/d. The shortest period of time of administration was one year, while the longest period was 11 years. As early as after one month there was a marked decrease of total cholesterol, LDL-cholesterol, lipoprotein Apo-B on the average by 39%; the increase of HDL cholesterol or lipoprotein Apo-A1 was marginal – up to 5% and the changes in triglycerides were not significant. There were not any untoward effects and the sexual and hormonal development was not influenced. The originally increased levels of total bilirubin were explained in the course of the study by the presence of heterozygous or homozygous mutation for the Gilbert disease. Examples of monitoring of typical patients are presented.
familial hypercholesterolemia, children, adolescents, drug treatment
General practitioner for children and adolescents